Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MNPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMNPRMonopar Therapeutics$37.69-9.0%$38.09$1.72▼$54.30$230.56M1.18358,363 shs2,825 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMNPRMonopar Therapeutics+8.64%-7.49%+33.04%+68.73%+1,023.20%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMNPRMonopar Therapeutics1.1518 of 5 stars1.54.00.00.03.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMNPRMonopar Therapeutics 3.00Buy$44.0016.76% UpsideCurrent Analyst Ratings BreakdownLatest MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2025MNPRMonopar TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$76.001/22/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $40.001/10/2025MNPRMonopar TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$72.00(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMNPRMonopar TherapeuticsN/AN/AN/AN/A$1.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMNPRMonopar Therapeutics-$8.40M-$1.97N/AN/AN/AN/A-107.21%-87.57%5/7/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMNPRMonopar TherapeuticsN/A5.415.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMNPRMonopar Therapeutics1.83%Insider OwnershipCompanyInsider OwnershipMNPRMonopar Therapeutics34.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMNPRMonopar Therapeutics106.10 million3.97 millionNot OptionableMNPR HeadlinesRecent News About These CompaniesHere's Why Momentum in Monopar Therapeutics (MNPR) Should Keep goingMarch 21, 2025 | zacks.comMonopar Therapeutics' (MNPR) "Overweight" Rating Reaffirmed at Piper SandlerMarch 20, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Receives Overweight Rating from Piper SandlerMarch 20, 2025 | americanbankingnews.comMonopar Therapeutics (MNPR) to Release Quarterly Earnings on ThursdayMarch 20, 2025 | marketbeat.comMonopar Therapeutics assumed with an Overweight at Piper SandlerMarch 19, 2025 | markets.businessinsider.comWhy Monopar Therapeutics Inc.’s (MNPR) Stock Is Up 15.06%March 18, 2025 | aaii.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Growth in Short InterestMarch 16, 2025 | marketbeat.comMonopar Therapeutics appoints new CFOMarch 5, 2025 | investing.comMonopar Therapeutics: Strong Data, But There Are RisksMarch 4, 2025 | seekingalpha.comMonopar Therapeutics Appoints Quan Vu as New CFOMarch 3, 2025 | tipranks.comMonopar Therapeutics Appoints Lavina Talukdar to BoardFebruary 24, 2025 | tipranks.comWhy Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025February 3, 2025 | msn.comWhy Monopar Therapeutics Inc.’s (MNPR) Stock Is Up 24.76%January 28, 2025 | aaii.comRosalind Franklin University's Helix 51 Incubator Welcomes Monopar TherapeuticsJanuary 23, 2025 | prnewswire.comMonopar Therapeutics price target raised to $40 from $22 at H.C. WainwrightJanuary 23, 2025 | finance.yahoo.comMonopar Therapeutics Gains ‘Buy’ Rating Amid Promising Licensing Deal with AstraZeneca and Strong Growth ProspectsJanuary 22, 2025 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Monopar Therapeutics Inc (MNPR), Nektar Therapeutics (NKTR)January 22, 2025 | markets.businessinsider.comMonopar Therapeutics files to sell 882,761 shares of common stock for holdersJanuary 16, 2025 | markets.businessinsider.com(MNPR) Trading AdviceJanuary 11, 2025 | news.stocktradersdaily.comPiper Sandler Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight RecommendationJanuary 10, 2025 | msn.comMonopar Therapeutics initiated with an Overweight at Piper SandlerJanuary 10, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNPR Company DescriptionsMonopar Therapeutics NASDAQ:MNPR$37.68 -3.71 (-8.95%) As of 10:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Microsoft’s Big Malaysia Bet Could Pay Off for Investors Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Maybe It’s Time to Buy Some GameStop Stock Intel's Strategy to Win the Next AI Frontier Is Alphabet Too Cheap to Ignore After Its Recent Correction? Qualcomm Stock Is Coiling for a Breakout Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
